Behind the ADRIATIC Trial in Limited-Stage SCLC
David Spigel, MD, explains some of the unmet needs for patients with limited-stage small cell lung cancer and how they led to the initiation of the ADRIATIC trial.
David Spigel, MD, chief scientific officer at Sarah Cannon Research Institute in Nashville, Tennessee, explains some of the unmet needs for patients with limited-stage small cell lung cancer (SCLC) and how they led to the initiation of the ADRIATIC trial (NCT03703297).
The phase 3, double-blind, placebo-controlled ADRIATIC study sought to evaluate treatment with durvalumab (Imfinzi) when used as consolidation therapy for patients with limited-stage SCLC that had not worsened after standard chemoradiotherapy. Patients were randomized to receive either durvalumab with placebo, durvalumab with tremelimumab (Imjudo), or placebo alone.
The first planned interim analysis of the primary end points for durvalumab vs placebo was recently presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. That analysis at ASCO had 2 primary end points: overall survival and progression-free survival by blinded independent central review.
Transcription:
0:09 | This study was looking at patients with limited-stage small cell lung cancer. This is something that [we are] seeing at different rates around the world in high smoking areas. It [makes up] about 20% of all lung cancer.In other areas it may be as low as 10%. But the cancers are very aggressive. For most patients, when small cell lung cancer is diagnosed, it has already spread. But about one-third of patients will have small cell lung cancer that still is curable in something we call limited-stage.
0:47 | The standard of care for many decades has been to give chemotherapy and radiation together for patients with hopefully curable small cell lung cancer. But even with that, most patients will have their cancer return within 2 years, and probably less than one-third will survive beyond 5 years. ADRIATIC was designed to see if immunotherapy—in the case of this analysis, we presented durvalumab, a PD-L1 antibody—can improve how patients did after that standard of chemotherapy and radiation given together.
Transcription created with AI and edited for clarity.
